Tag: biopharmaceuticals

ImmunOs Therapeutics Raises $74 Million Series B Financing Round

– New investors Samsara, Lightspeed, Gimv, and Mission BioCapital further strengthen investor base and expand transatlantic footprint

– Company establishes U.S. subsidiary to accelerate international operations

ImmunOs Therapeutics AG, a biopharmaceutical company leveraging its HLA-based technology platform to develop first-in-class therapeutics for the treatment of cancer and autoimmune diseases, today announced the closing of an oversubscribed Series B financing round totaling $74 million. The round was led by new investors Samsara BioCapital, Lightspeed Venture Partners, and Gimv, and joined by new investors Mission BioCapital, GL Capital, PEAK6 Strategic Capital, and Fiscus Financial, as well as existing investors Pfizer Ventures, BioMed Partners, and Schroder Adveq. Read more…

Company News: MediGene Signs Commercialization Agreement for Veregen / ProBioGen Is Granted New Divisional Patent on Duck Cell Line

MediGene AG has signed a license and supply agreement with Meditrina Pharmaceuticals for the supply and commercialization of Veregen® in Greece and Cyprus. Meditrina will promote and distribute Veregen® for the treatment of genital warts in both territories. Upon the achievement of specific milestones, MediGene will be entitled to successive payments totaling up to 900 thousand euros, and will receive the first milestone payment upon the initiation of the approval procedure in Greece. In addition, MediGene will supply Meditrina with finished product and will receive double-digit royalties on net sales. MediGene believes that Greece is the sixth largest potential European market for Veregen® sales volume.

MediGene has already entered into marketing partnerships for Veregen® with Nycomed, Inc. for the USA, Solvay (acquired by Abbott on February 15, 2010) for Germany, Austria and Switzerland, Juste S.A.Q.F for Spain and Portugal and Teva Pharmaceuticals Industries Ltd. for Israel. For further information, please click here.

Also today, ProBioGen has announced that it has been granted a divisional patent on its prorietary AGE1 cell line.
The patent covers the production of Modified Vaccinia Ankara (MVA) in duck cell lines. As these cells are free from endogenous particle-associated retrovirus activity, they are superior to current production substrates derived from chicken. The discovery has wide implications for the industrial production of one of the most promising recombinant vaccine vectors against infectious disease challenges such as HIV and malaria. Read more here.

Company News: Affectis Pharmaceuticals Raises €3.3M in Financing and Names Alex Martin Chief Executive Officer

Affectis Pharmaceuticals AG today announced it has raised €3.3M in the first tranche of a Series D financing. Existing investors LSP, Aescap Venture, KfW, Bayernkapital and EMBL Ventures were participating in the round. Moreover, the company announced the appointment of Alex Martin as Chief Executive Officer. Mr. Martin had previously served on the Supervisory Board of Affectis and joined the company fulltime as CFO in August of 2009. He succeeds founding CEO Herbert Stadler, who is retiring.

Mr. Martin brings over 20 years experience in the pharmaceutical industry, including roles at Novartis, where he was Vice President, Global Business Development & Licensing, and SmithKline Beecham where he held positions of increasing responsibility in sales, marketing, and business development. Immediately prior to Affectis Mr. Martin served as COO of Intercept Pharmaceuticals based in New York.

The full announcement is available at Affectis’  website.

Company News: Micromet Closes $80.5 Million Public Offering of Common Stock

Micromet, Inc. (NASDAQ: MITI) announced today the closing of its previously announced underwritten public offering and raises net proceeds of approximately $ 75.3 million, after deducting the underwriting discount and estimated offering expenses. For more information, please click here.